Panel Discussion: The Race to Market Share: Is the Answer Ending the Burden of Monthly Treatments?

Time: 4:10 pm
day: Day One


  • Longer-term VEGF inhibition is needed to combat the burden of monthly treatments. This panel will explore extended-duration therapeutic possibilities with a focus on the anti-VEGF pathway to reduce the number of times the patient has to visit the clinic and the side effects of the therapeutic. It will also touch on the question – is the way to gain market from proprietary biologic holders through extended-release or duration?
  • Whether it’s gene therapy, oral therapeutics or combination approaches, how do we get these drugs to last longer and bring the convenience of drug delivery to the patient while ensuring they are safe?